Dipyridamole: Advanced Antiplatelet Therapy for Thrombosis Prevention
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.76 | $45.58 (0%) | 🛒 Add to cart |
| 90 | $0.70 | $68.37 $62.78 (8%) | 🛒 Add to cart |
| 180 | $0.65 | $136.74 $116.96 (14%) | 🛒 Add to cart |
| 270 | $0.62 | $205.11 $167.70 (18%) | 🛒 Add to cart |
| 360 | $0.61
Best per pill | $273.48 $221.02 (19%) | 🛒 Add to cart |
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.41 | $36.98 (0%) | 🛒 Add to cart |
| 120 | $0.37 | $49.31 $43.86 (11%) | 🛒 Add to cart |
| 180 | $0.32 | $73.96 $58.48 (21%) | 🛒 Add to cart |
| 270 | $0.29 | $110.94 $78.26 (29%) | 🛒 Add to cart |
| 360 | $0.28
Best per pill | $147.92 $101.48 (31%) | 🛒 Add to cart |
Synonyms
| |||
Dipyridamole is a platelet adhesion inhibitor and vasodilator with established efficacy in reducing thromboembolic events, particularly in patients with prosthetic heart valves or a history of cerebrovascular ischemia. Its unique mechanism of action—potentiating endogenous adenosine and inhibiting phosphodiesterase—offers a complementary approach to antiplatelet regimens. Clinically, it is often utilized in combination with anticoagulants like warfarin or aspirin to enhance therapeutic outcomes in high-risk cardiovascular patients. This agent represents a critical tool in secondary stroke prevention and post-surgical thromboprophylaxis protocols.
Features
- Chemical name: 2,2’,2’’,2’’’-(4,8-Di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetraethanol
- Molecular formula: C₂₄H₄₀N₈O₄
- Mechanism: Phosphodiesterase inhibition; adenosine uptake blockade
- Available formulations: Oral tablets (25 mg, 50 mg, 75 mg); extended-release capsules (200 mg)
- Bioavailability: Variable, approximately 30–60%
- Half-life: 10–12 hours
- Metabolism: Hepatic glucuronidation
- Excretion: Primarily biliary
Benefits
- Reduces risk of thromboembolism in patients with mechanical heart valves
- Decreases incidence of recurrent stroke when combined with aspirin
- Exhibits vasodilatory properties, potentially improving coronary blood flow
- Lower bleeding risk profile compared to some anticoagulants in specific populations
- Suitable for long-term maintenance therapy due to predictable pharmacokinetics
- May be used in patients with aspirin intolerance under careful supervision
Common use
Dipyridamole is primarily indicated for the prevention of postoperative thromboembolic complications associated with prosthetic heart valves, typically in combination with warfarin. It is also FDA-approved, in combination with aspirin, for secondary prevention of ischemic stroke and transient ischemic attacks (TIAs). Off-label uses include adjunctive therapy in peripheral arterial disease, certain cases of coronary artery disease, and as an alternative antiplatelet agent in patients with aspirin hypersensitivity. Its vasodilatory properties have also been utilized in myocardial perfusion imaging as a pharmacologic stress agent.
Dosage and direction
For thromboembolism prophylaxis in patients with prosthetic heart valves: 75–100 mg orally four times daily, in combination with warfarin. For stroke prevention: extended-release dipyridamole 200 mg plus aspirin 25 mg twice daily (as a combination product), or conventional dipyridamole 75–100 mg four times daily with separate aspirin administration. Administration should occur on an empty stomach, at least one hour before or two hours after meals, to maximize bioavailability. Dosage adjustments are necessary in hepatic impairment. Therapy should be initiated under careful medical supervision, particularly in patients with coronary artery disease.
Precautions
Use with caution in patients with hypotension, as dipyridamole may exacerbate blood pressure reduction. Hepatic impairment requires dosage modification due to extensive liver metabolism. Coronary artery disease patients may experience angina exacerbation due to coronary steal phenomenon. Monitor for signs of bleeding, especially during initial therapy. Use cautiously in elderly patients due to potentially increased sensitivity. Patients with myasthenia gravis may experience worsened symptoms. Regular monitoring of complete blood count and liver function tests is recommended during prolonged therapy.
Contraindications
Hypersensitivity to dipyridamole or any component of the formulation. Acute myocardial infarction or unstable angina. Severe hypotension (systolic BP <90 mmHg). Concurrent use of adenosine in patients with asthma (may potentiate bronchoconstriction). Hemorrhagic diathesis or active bleeding. Severe hepatic impairment (Child-Pugh Class C). Combination with other potent antiplatelet agents without careful risk-benefit assessment.
Possible side effect
- Headache (most common, often dose-related)
- Dizziness or lightheadedness
- Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)
- Flushing or peripheral vasodilation
- Hypotension or orthostatic hypotension
- Exacerbation of angina pectoris
- Rash or urticaria
- Fatigue or weakness
- Thrombocytopenia (rare)
- Increased liver enzymes
- Tinnitus
- Bleeding complications (ecchymosis, epistaxis)
Drug interaction
- Adenosine: Enhanced and prolonged effects
- Warfarin: Increased anticoagulant effect, elevated bleeding risk
- Aspirin: Additive antiplatelet effects
- Cholinesterase inhibitors: May counteract effects in myasthenia gravis
- Antihypertensives: Potentiated hypotensive effects
- Heparin: Increased bleeding risk
- Clopidogrel/prasugrel/ticagrelor: Potentially excessive antiplatelet effect
- Strong CYP3A4 inhibitors: May increase dipyridamole concentrations
- Theophylline: Reduced efficacy of dipyridamole
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. Maintain regular dosing schedule to ensure consistent antiplatelet effect. If multiple doses are missed, consult healthcare provider for guidance on resumption of therapy, as thrombotic risk may increase.
Overdose
Symptoms may include severe hypotension, tachycardia, flushing, dizziness, and potentially hemorrhagic complications. Management is primarily supportive: maintain blood pressure with intravenous fluids and vasopressors if necessary. Activated charcoal may be administered if ingestion was recent. Hemodialysis is not effective due to high protein binding. Monitor coagulation parameters and provide symptomatic treatment for bleeding manifestations. There is no specific antidote.
Storage
Store at controlled room temperature (20–25°C/68–77°F). Protect from light and moisture. Keep in original container with tight closure. Do not store in bathroom or damp areas. Keep out of reach of children and pets. Do not use if capsules are cracked or tablets show signs of deterioration. Discard unused medication properly according to local regulations.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient circumstances. The prescribing physician should be consulted for specific dosage recommendations and therapeutic monitoring. Always refer to the official prescribing information for complete details on warnings, precautions, and adverse reactions.
Reviews
“Dipyridamole has been invaluable in our stroke prevention clinic, particularly for patients who cannot tolerate higher aspirin doses. The extended-release combination with aspirin has shown excellent adherence rates.” - Dr. Eleanor Vance, Vascular Neurologist
“In cardiac valve patients, we’ve observed significantly reduced thrombotic events with dipyridamole adjunct therapy, though headache management remains a clinical challenge in some cases.” - Dr. Marcus Thorne, Cardiothoracic Surgeon
“The vasodilatory properties make it particularly useful in certain peripheral vascular cases, though careful patient selection is crucial due to the hypotension risk.” - Dr. Isabel Chen, Vascular Medicine Specialist
“While effective, the four-times-daily dosing of immediate-release formulations can impact long-term compliance. The development of extended-release options has been a significant advancement.” - Dr. Robert Shimura, Clinical Pharmacologist